Clinical results for zorevunersen, a one‑time gene regulation therapy for Dravet syndrome, showed substantial seizure reductions in pediatric patients and improved functional outcomes, according to data published in the New England Journal of Medicine. Trial participants experienced between 59% and 91% fewer seizures over 20 months compared with baseline in the reported cohorts. The multi‑site investigator team from University College London, Great Ormond Street Hospital and U.S. centers reported favorable tolerability with mostly moderate adverse events. The Phase 3 randomized trial is ongoing to validate these open‑label and early controlled findings. If confirmed in randomized pivotal testing, zorevunersen would represent one of the first gene‑regulatory approaches to produce large, durable clinical benefit in a severe pediatric epileptic encephalopathy—an outcome with major implications for rare‑disease trial design and regulatory engagement.